Preclinical studies of the serotonin 2A (5-HT2A) antagonist deramciclane suggested an anxiolytic profile, which has not been unequivocally established in the clinic. The same receptor profile also indicated that the compound may exhibit antidepressant potential. However, evidence for these effects remains inconclusive. The present study examined the effect of the drug in two preclinical tests with predictive validity for antidepressant activity.

Scientists unlock the mechanism behind C. diff’s most harmful toxin, opening the door to more targeted treatments that protect gut health and prevent disease recurrence. 

The discharge and prevalence of psychoactive drugs in surface waters has raised concerns about potential risks to ecosystems and public health. Yet there is limited information on the ecotoxicity of these compounds in marine environments and aquaculture. 

Five LMU researchers have been awarded Consolidator Grants by the European Research Council. Their projects deal with climate change, strokes, quantum physics, mitochondria, and cancer diagnosis.

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia were able to maintain safe platelet counts without serious bleeding episodes for at least one year. 

The results were published today in the New England Journal of Medicine, by researchers from the Perelman School of Medicine at the University of Pennsylvania, and presented by collaborators at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Orlando, Florida (LBA-2).